TUMAGNOSTIC
Financiado
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: a...
A disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach
TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours. CP-506 overcomes the limitations of previous HA...
TUMAGOSTIC will advance the development of CP-506, a next-generation Hypoxia Activated Prodrug (HAP) for the treatment of hypoxic tumours, representing over 50% of all solid tumours. CP-506 overcomes the limitations of previous HAP development attempts and can provide more targeted treatment compared with alternatives such as chemo-immunotherapy combination and PARPi. Our approach, combining CP-506 with improved patient targeting based on two AI-driven biomarkers (tumour hypoxia and Homologous Recombination Defect), has high potential to increase the effectiveness of standard of care therapies such as immunotherapy (IO) in combination therapy (prodrug-IO) and improve patients’ progression free survival and quality of life in several cancer types. We aim to advance CP-506 towards commercialization by carrying out a phase I-IIa clinical trial and corresponding business development activities, paving the way for a licensing agreement with the potential to exceed €450M.
ver más
Duración del proyecto: 24 meses
Fecha Inicio: 2023-12-21
Fecha Fin: 2025-12-31
Fecha Fin: 2025-12-31
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-21
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2023-ACCELERATOROPEN-01:
EIC Accelerator Open 2023
Cerrada
hace 1 año
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
CONVERT PHARMACEUTICALS
No se ha especificado una descripción o un objeto social para esta compañía.
